Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?

The disease caused by the new coronavirus SARS-CoV-2 (COVID-19) is currently spread worldwide . Recent data supports SARS-CoV-2 may use integrins to enter human cells. Therefore, anti-integrins therapies might be an alternative against the infection . Natalizumab, approved for Multiple Sclerosis (MS...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguirre, Clara, Meca-Lallana, Virginia, Barrios-Blandino, Ana, del Río, Beatriz, Vivancos, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831671/
https://www.ncbi.nlm.nih.gov/pubmed/32531754
http://dx.doi.org/10.1016/j.msard.2020.102250
_version_ 1783641667652288512
author Aguirre, Clara
Meca-Lallana, Virginia
Barrios-Blandino, Ana
del Río, Beatriz
Vivancos, Jose
author_facet Aguirre, Clara
Meca-Lallana, Virginia
Barrios-Blandino, Ana
del Río, Beatriz
Vivancos, Jose
author_sort Aguirre, Clara
collection PubMed
description The disease caused by the new coronavirus SARS-CoV-2 (COVID-19) is currently spread worldwide . Recent data supports SARS-CoV-2 may use integrins to enter human cells. Therefore, anti-integrins therapies might be an alternative against the infection . Natalizumab, approved for Multiple Sclerosis (MS) treatment, acts blocking α4-integrin. We report a MS patient treated with natalizumab who develops COVID-19, with excellent recovery and repeated negative results in 5 consecutive microbiological studies. We postulate this may be due to the blockade of integrins induced by natalizumab.
format Online
Article
Text
id pubmed-7831671
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-78316712021-01-26 Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role? Aguirre, Clara Meca-Lallana, Virginia Barrios-Blandino, Ana del Río, Beatriz Vivancos, Jose Mult Scler Relat Disord Correspondence The disease caused by the new coronavirus SARS-CoV-2 (COVID-19) is currently spread worldwide . Recent data supports SARS-CoV-2 may use integrins to enter human cells. Therefore, anti-integrins therapies might be an alternative against the infection . Natalizumab, approved for Multiple Sclerosis (MS) treatment, acts blocking α4-integrin. We report a MS patient treated with natalizumab who develops COVID-19, with excellent recovery and repeated negative results in 5 consecutive microbiological studies. We postulate this may be due to the blockade of integrins induced by natalizumab. Elsevier B.V. 2020-09 2020-06-03 /pmc/articles/PMC7831671/ /pubmed/32531754 http://dx.doi.org/10.1016/j.msard.2020.102250 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Aguirre, Clara
Meca-Lallana, Virginia
Barrios-Blandino, Ana
del Río, Beatriz
Vivancos, Jose
Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
title Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
title_full Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
title_fullStr Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
title_full_unstemmed Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
title_short Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
title_sort covid-19 in a patient with multiple sclerosis treated with natalizumab: may the blockade of integrins have a protective role?
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831671/
https://www.ncbi.nlm.nih.gov/pubmed/32531754
http://dx.doi.org/10.1016/j.msard.2020.102250
work_keys_str_mv AT aguirreclara covid19inapatientwithmultiplesclerosistreatedwithnatalizumabmaytheblockadeofintegrinshaveaprotectiverole
AT mecalallanavirginia covid19inapatientwithmultiplesclerosistreatedwithnatalizumabmaytheblockadeofintegrinshaveaprotectiverole
AT barriosblandinoana covid19inapatientwithmultiplesclerosistreatedwithnatalizumabmaytheblockadeofintegrinshaveaprotectiverole
AT delriobeatriz covid19inapatientwithmultiplesclerosistreatedwithnatalizumabmaytheblockadeofintegrinshaveaprotectiverole
AT vivancosjose covid19inapatientwithmultiplesclerosistreatedwithnatalizumabmaytheblockadeofintegrinshaveaprotectiverole

Ejemplares similares